Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver Disease

NCT03060538 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT03060538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03060538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus and Patients With Non-Alcoholic Fatty Liver Disease
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 5, 2017
Completion date
December 13, 2019
Enrollment
154 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 2, non-alcoholic fatty liver disease